YB1 lysing bacterium opens a new pathway for cancer immunotherapy as oncology drug market battles rage on
The development and advancement of technology have greatly improved the quality of life of people, yet today, cancer is still a severe threat to human life and health. Broadly speaking, cancer is a collective term for all malignant tumours, which manifest as uncontrolled cell division and multiplication. Types of cancer are usually classified as haematological malignancies or solid tumours and are a significant cause of death worldwide, in addition to cardiovascular disease.
Cancer has been widely perceived as a synonym for the most lethal of all diseases. Although the last few decades have seen considerable success in the global cancer treatment field, with many cancers moving from being “incurable” to chronic diseases that can be treated on a sustainable basis, the label of cancer as a deadly and incurable disease has not been removed. However, the label of cancer as a deadly and incurable disease has not been removed.
According to one study, the overall five-year survival rate for cancer patients in China is 40.5%, compared to 67.1% for cancer patients in the United States.
Tips: The five-year survival rate refers to the proportion of a tumour that survives for more than five years after various combination treatments.
The expression of five-year survival rate has its specific scientific nature: after the treatment of tumour, some of them may develop metastasis and recurrence, and some of them may die because the tumour enters advanced stage; metastasis and recurrence mainly occur within three years after radical surgery, accounting for about 80%, and a few occur within five years after radical surgery, accounting for about 10%. Therefore, the chance of recurrence is rare if the tumour does not recur within five years after radical surgery for various tumours, so the five-year survival rate is commonly used to indicate the efficacy of various cancers.
Public statistics for 2019 show that the five most common types of cancer in China are lung, stomach, colorectal, liver and thyroid cancers, while the five most common types of cancer in the United States are breast, lung, prostate, colorectal and skin cancers.
Strong growth in the global oncology drug market as new cancer cases continue to rise.
Currently, the number of new cancer cases continues to rise globally and in China. Industry research reports track data showing that there will be 18.5 million new cancer cases worldwide in 2019, with 21 million expected in 2024 and 24.1 million in 2030, representing a compound annual growth rate of 2.5% from 2019 to 2024 and 2.4% from 2024 to 2030.
There were 4.4 million new cancer cases in China in 2019, which is projected to increase by 5 million in 2024 and 5.7 million in 2030. a compound annual growth rate of 2.5 per cent from 2019 to 2024 and 2.2 per cent from 2024 to 2030.
At the same time, the global oncology market and the Chinese and US oncology markets are growing strongly, well ahead of the growth in new cancer cases, and are expected to continue to expand at a rapid pace in the recent future.
According to statistics, the worldwide oncology medication market is projected to reach US$143.5 billion in 2019, US$244.4 billion in 2024, and US$391.3 billion in 2030. It is expanding at a CAGR of 11.2 per cent from 2019 to 2024 and 8.2 per cent from 2024 to 2030.
China’s cancer medication market is projected to reach US$26.4 billion in 2019, US$53.1 billion in 2024, and US$95.5 billion in 2030, expanding at a 15.0 per cent compound annual growth rate from 2019 to 2024 and 10.3 per cent from 2024 to 2030. In the United States, the cancer medication market projecting to reach $67.8 billion in 2019, $115.2 billion in 2024, and US$179.7 billion in 2030, expanding at an 11.2 per cent compound annual growth rate from 2019 to 2024 and 7.7 per cent from 2024 to 2030.
Immunotherapy continues to gain momentum and will ‘rule’ the cancer treatment field with targeted therapies in the future.
The global oncology drugs market is dominated by targeted therapeutics, using publicly available data for 2019 as an example. In terms of sales revenue, targeted therapeutics accounted for 62.7% of the total global oncology drugs market, while chemotherapeutics and immunotherapeutics accounted for 17.1% and 20.3% of the market, respectively.
Specialist research institutes predict that by 2030, the global oncology drugs market will be dominated by targeted therapeutics and immunotherapeutics, which will account for 49.5% and 44% of the global oncology drugs market, respectively, in terms of sales revenue, while chemotherapeutics are expected to account for only 6.6% of the remaining global oncology drugs market.
As for the domestic market, the Chinese oncology drug market in 2019 was dominated by chemotherapy drugs, which accounted for 72.6% of the Chinese oncology drug market in terms of sales revenue, while targeted therapeutics and immunotherapeutics accounted for only 23.4% and 4% of the market, respectively.
However, by 2030, the market for targeted therapeutics and immunotherapeutics will grow significantly, with the share of revenue overtaking that of traditional chemotherapeutics across the board. In terms of sales revenue, targeted therapeutics are expected to account for 54.0% of the Chinese oncology drug market in 2030, while immunotherapeutics and chemotherapeutics are expected to account for 35.7% and 10.3% of the Chinese oncology drug market, respectively.
Therefore, in the next 10 years, the global market for immunotherapy and targeted therapies in cancer treatment will continue to grow explosively. It is not an exaggeration to say that immunotherapy will “rule” the cancer treatment field together with targeted therapies.
YB1 oncolytic bacterial immunotherapy — charting a course for differentiated cancer treatment
Looking back over the last few decades, the mainstream approach to cancer treatment has evolved from traditional methods such as surgery, radiotherapy, and chemotherapy to emerging approaches such as targeted tumor therapy and tumor immunotherapy, which are more advanced in terms of improving patient outcomes while minimizing systemic adverse reactions to treatment.
However, competition in the field of oncology treatment at home and abroad has now become fierce, with the rivalry between the enormous enterprise not stopping, and an increasing number of new entrants.
The field of immunotherapy, an emerging pillar of anti-tumour therapy, has seen the emergence of many cutting-edge segments, including antibody-based therapies such as PD1, PDL1 and CTLA4, CAR-T cell therapies, immune vaccines, oncolytic virus and oncolytic bacterial, among others. With a dizzying array of innovative therapies, it is crucial for industry players to find ways to differentiate themselves in the face of intense competition.
HKND YB1is the first biotechnology company to successfully modify and invent an oncolytic bacterial product through synthetic biology technology that precisely targets the hypoxic region inside the tumour. Through independent research, we have successfully invented an oncolytic bacterial cancer immunotherapy method with high safety and efficacy, achieving a new breakthrough in the field of bacterial vector technology.
As the world’s first major competitor in the lysing bacterium track, HKND YB1has invented the world’s first lysing bacterium vector, YB1, As the core technology product of the company, oncolytic bacterial vector YB1 adopts the unique tumour hypoxia-specific targeting technology, which can spontaneously crack and die with high oxygen content (> 0.5%), do not damage normal organs. In comparison, in low oxygen situation (oxygen concentration below 0.5%), it will rapidly proliferate and release the carrying warhead drugs, attacking the tumour to exert an oncolytic effect.
Our YB1-related technological innovation has been patented as the world’s first oxygen-regulated oncolytic bacterial, with patents issued in China, the United States of America, and the European Union. YB1 is now being used clinically to treat primary malignancies in dogs, including malignant sarcoma, melanoma, breast cancer, prostate cancer, and lymphoma, among others.
Experimental results have shown the efficacy of YB1 oncolytic bacterial therapy in the treatment of cancer in pets, with some dogs cured by YB1 remaining cancer-free for 5 years to date.
In addition to cancer immunotherapy, YB1 can also be used in combination with thrombolytic drugs to treat various thrombotic diseases. The company has already established several novel thrombolytic drug pipelines. We look forward to advancing the application of YB1 technology and broadening the development of the emerging carrier technology industry through the investigation of oncolytic bacterial cancer immunotherapy thrombolytic therapy.